Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05007860 · ClinicalTrials.gov registry record
Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 36
- Enrollment target
NCT05007860: Completed study, sponsored by Massachusetts General Hospital.
NCT05007860 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05007860 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
Assessment of SARS-CoV2 (mRNA and adenovirus-based vaccines) and Conjugated Pneumococcal (PCV13) in Patients with Chronic Lymphocytic Leukemia
Interventions
- BIOLOGICAL PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05007860
The ClinicalTrials.gov registry entry for NCT05007860 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability. is the first listed.
NCT05007860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05007860 about?
NCT05007860 is a clinical study titled "Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia". Assessment of SARS-CoV2 (mRNA and adenovirus-based vaccines) and Conjugated Pneumococcal (PCV13) in Patients with Chronic Lymphocytic Leukemia
What is the current status of trial NCT05007860?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2020-07-16. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05007860?
The interventions under investigation include: PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability. (BIOLOGICAL).
Who is sponsoring clinical trial NCT05007860?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.